All posts by: Michael Zand

About Michael Zand

CAR T-Cell Therapy for Leukemia Leads to Remissions in Clinical Trial – Newswise (press release)

Continue reading

2017-07-18 NEWS

The Straits Times

CAR T-Cell Therapy for Leukemia Leads to Remissions in Clinical Trial
Newswise (press release)
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our study shows that CD19 CAR T-cells are a highly promising treatment for CLL …
Promising immunotherapy helps adults with leukemiaDaily Mail

all 8 news articles »

Continue reading

2017-07-18 NEWS

CAR T-Cell Therapy for Leukemia Leads to Remissions in Clinical Trial
Newswise (press release)
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our study shows that CD19 CAR T-cells are a highly promising treatment for CLL …

Continue reading

2017-07-18 NEWS

Inquirer.net

Promising immunotherapy helps adults with leukemia
Inquirer.net
MIAMI—A cancer treatment that genetically alters immune cells has shown success in 71 percent of adults with the most common form of leukemia, and for whom other medicines had failed, US researchers said Monday. The treatment, known as experimental …

and more »

Continue reading

2017-07-18 NEWS

Global Market Study on Allergic Rhinitis Treatment: Immunotherapy Treatment Segment Projected to be the Fastest …
PR Newswire (press release)
LONDON, July 17, 2017 /PRNewswire/ — Persistence Market Research in its recent report “Allergic Rhinitis Treatment Market: 2016–2024,” examines the global allergic rhinitis treatment market for the period of eight years. i.e. 2016-2024. The primary …

and more »

Continue reading

2017-07-17 NEWS

Capitol Weekly

LAT: ‘Secret Life’ of former USC Med School dean, stem cell agency director
Capitol Weekly
He still serves, as a gubernatorial appointee, on the board of the California Institute for Regenerative Medicine (CIRM), as the stem cell agency is formally known. The board position pays $100 a day for meeting attendance. The board meets 10 to 12
An overdose, a young companion, drug-fueled parties: The secret life of USC med school deanLos Angeles Times

all 19 news articles »